-
1Academic Journal
Authors: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, A. A. Izmaylov, R. R. Muginov, I. A. Menshikova, I. A. Sharifgaleev, D. O. Lipatov, N. I. Sultanbaeva, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, А. A. Измайлов, Р. Р. Мугинов, И. А. Меньшикова, И. А. Шарифгалеев, Д. О. Липатов, Н. И. Султанбаева
Source: Cancer Urology; Том 17, № 2 (2021); 174-181 ; Онкоурология; Том 17, № 2 (2021); 174-181 ; 1996-1812 ; 1726-9776
Subject Terms: кабозантиниб, metastasis to the external genital organs, sanitation vulvectomy, palliative nephrectomy, tyrosine kinase inhibitor, cabozantinib, метастаз в наружные половые органы, санационная вульвэктомия, паллиативная нефрэктомия, тирозинкиназный ингибитор
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1469/1283; Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2016. CA Cancer J Clin 2016;66(1):7-30. DOI:10.3322/caac.21332.; Scelo G., Larose T.L. Epidemiology and risk factors for kidney cancer. J Clin Oncol 2018;36(36):JCO2018791905. DOI:10.1200/JCO.2018.79.1905.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7-30. DOI:10.3322/caac.21442.; Bhatt J.R., Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol 2014;11(9):517-25. DOI:10.1038/nrurol.2014.194.; Shuch B., Amin A., Armstrong A.J. et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol 2015;67(1):85-97. DOI:10.1016/j.eururo.2014.04.029.; Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7-30. DOI:10.3322/caac.21387.; Motzer R.J., Bukowski R.M., Figlin R.A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113(7):1552-8. DOI:10.1002/cncr.23776.; Nerich V., Hugues M., Paillard M.J. et al. Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. Onco Targets Ther 2014;7:365-74. DOI:10.2147/OTT.S56370.; Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старин-ского, А.О. Шахазадовой. М.: МНИОИ им. П.А. Герцена -филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.; Gupta K., Miller J.D., Li J.Z. et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34(3):193-205. DOI:10.1016/j.ctrv.2007.12.001.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5-29. DOI:10.3322/caac.21254.; Hanno P., Wein A., Malkowicz S.B. Clinical Manual of Urology. 3rd edn. New York: McGraw Hill, 2001. 498 p.; Vidart A., Fehri K., Pfister C. Unusual metastasis of renal carcinoma. Ann Urol (Paris) 2006;40(4):211-9. DOI:10.1016/j.anuro.2006.03.004.; D'Elia C., Cai T., Luciani L. et al. Pelvic and muscular metastasis of a renal cell carcinoma: a case report. Oncol Lett 2013;5(4):1258-60. DOI:10.3892/ol.2013.1172.; Menon A.R., Thomas A.S., Suresh N., Shashidhar S.M. Cutaneous metastasis: an unusual presenting feature of urologic malignancies. Urol Ann 2016;8(3):377-80. DOI:10.4103/0974-7796.184882.; Mueller T.J., Wu H., Greenberg R.E. et al. Cutaneous metastases from genitourinary malignancies. Urology 2004;63(6):1021-6. DOI:10.1016/j.urology.2004.01.014.; Kramer D.E., Kerolus M.G., Tan L.A. et al. Embolization of an exophytic posterior neck mass secondary to a cutaneous renal cell carcinoma metastasis. Neurointervention 2020;15(3):162-6. DOI:10.5469/neuroint.2020.00206.; Saeed S., Keehn C.A., Morgan M.B. Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal. J Cutan Pathol 2004;31(6):419-30. DOI:10.1111/j.0303-6987.2004.00207.x.; Jin W.W., Chung J.M., Jung K.E. et al. A case of metastatic renal cell carcinoma mimicking granuloma pyogenicum. Ann Dermatol 2008;20(4):263-6. DOI:10.5021/ad.2008.20.4.263.; Schwartz R.A. Cutaneous metastatic disease. J Am Acad Dermatol 1995;33 (2 Pt 1):161-82.; Schlesinger-Raab A., Treiber U., Zaak D. et al. Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer 2008;44(16):2485-95. DOI:10.1016/j.ejca.2008.07.039.; Gravis G., Chanez B., Derosa L. et al. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urol Oncol 2016;34(4):167.e17-23. DOI:10.1016/j.urolonc.2015.10.015.; Xu Y., Hou R., Lu Q. et al. Renal clear cell carcinoma metastasis to the breast ten years after nephrectomy: a case report and literature review. Diagn Pathol 2017;12(1):76 DOI:10.1186/s13000-017-0666-8.; Motzer R.J., McCann L., Deen K. Pazopanib versus sunitinib in renal cancer. N Engl J Med 2013;369(20):1970. DOI:10.1056/NEJMc1311795.; Русаков И.Г., Грицкевич А.А., Байтман Т.П. и др. Сунитиниб в терапии метастатического почечноклеточного рака. Медицинский совет 2020;(9):136-45. [Rusakov I.G., Gritskevich A.A., Baytman T.P. et al. Sunitinib in the treatment of metastatic renal cell carcinoma. Meditsinskiy sovet = Medical Council 2020;(9):136-45. (In Russ.)]. DOI:10.21518/2079-701X-2020-9-136-145.; Qin S., Li A., Yi M. et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 2019;12(1):27. DOI:10.1186/s13045-019-0718-5.; Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77(9):1745-70. DOI:10.1007/s00018-019-03351-7.; Dufies M., Giuliano S., Ambrosetti D. et al. Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res 2017;77(5):1212-26. DOI:10.1158/0008-5472.CAN-16-3088.; Deleuze A., Saout J., Dugay F. et al. Immunotherapy in renal cell carcinoma: the future is now. Int J Mol Sci 2020;21(7):2532. DOI:10.3390/ijms21072532.; Gore M.E., Szczylik C., Porta C. et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015;113(1):12-9. DOI:10.1038/bjc.2015.196.; Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openlabel, phase 3 trial. Lancet Oncol 2016;17:917-27. DOI:10.1016/S1470-2045(16)30107-3.; Меньшиков К.В. Определение сторожевого лимфоузла при раке вульвы методами контрастной лимфографии и непрямой интраоперационной радиоизотопной лимфосцинтиграфии. Академический журнал Западной Сибири 2018;14(5 (76)):29-30.; Мухин А.А., Жаров А.В., Чернова Л.Ф. и др. Хирургическое лечение больных раком вульвы. Вопросы онкологии 2018;64(2):190-5.; Липатов О.Н., Меньшиков К.В., Султанбаев А.В. и др. Паллиативные операции при раке вульвы. Паллиативная медицина и реабилитация 2020;(4):41-5.; Ghebre R.G., Posthuma R., Vogel R.I. et al. Effect of age and comorbidity on the treatment and survival of older patients with vulvar cancer. Gynecol Oncol 2011;121(3):595-9. DOI:10.1016/j.ygyno.2011.02.005.; Yakes F.M., Chen J., Tan J. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298-308. DOI:10.1158/1535-7163.MCT-11-0264.; Katayama R., Kobayashi Y., Friboulet L. et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 2015;21(1):166-74. DOI:10.1158/1078-0432.CCR-14-1385.; Матвеев В.Б., Ольшанская А.С., Волкова М.И. Кабозантиниб: от исследований к реальной клинической практике. Онкоурология 2019;15(3):28-41. DOI:10.17650/1726-97762019-15-3-28-41.; Носов Д.А., Алексеев Б.Я., Волкова М.И. и др. Практические рекомендации по лекарственному лечению почечно-клеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).; George D.J., Hessel C., Halabi S. et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Clin Trial Oncol 2019;24(11):1497-501. DOI:10.1634/theoncologist.2019-0316.; Di Nunno V., Cimadamore A., Santoni M. et al. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castrationresistant prostate cancer. Fut Oncol 2018;14(25):2559-64. DOI:10.2217/fon-2018-0158.; Fioramonti M., Santini D., Iuliani M. et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. Oncotarget 2017;8(12):20113-21. DOI:10.18632/oncotarget.15390.; https://oncourology.abvpress.ru/oncur/article/view/1469
-
2Academic Journal
Authors: M. I. Volkova, V. A. Chernyaev, A. V. Klimov, A. D. Begaliev, S. M. Mkhitaryan, E. V. Ogorodnikova, V. B. Matveev, М. И. Волкова, В. А. Черняев, А. В. Климов, А. Д. Бегалиев, С. М. Мхитарян, Е. В. Огородникова, В. Б. Матвеев
Source: Cancer Urology; Том 14, № 1 (2018); 28-35 ; Онкоурология; Том 14, № 1 (2018); 28-35 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-1
Subject Terms: тромбэктомия, tumor venous thrombosis, pulmonary metastases, cytoreductive nephrectomy, inferior vena cava thrombectomy, опухолевый венозный тромбоз, метастазы в легкие, паллиативная нефрэктомия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/710/736; Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345: 1655-1659.; Mickisch GH, Garin A, van Poppel H, et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970; Heng, D. Y., Wells, J. C., Rini, B. I. et al.: Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 66: 704, 2014.; Hanna Nawar, Sun Maxine, Meyer Christian P. Et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study Journal of Clinical Oncology 34, no. 27 (September 2016) 3267-3275.; Давыдов М.И., Матвеев В.Б., Волкова М.И. и др. Факторы прогноза непосредственных результатов тромбэктомии у больных раком почки с опухолевым венозным тромбозом. Онкоурология. – 2014. - № 3. – 36 – 44.; Heng Daniel Y.C., Wanling Xie, Meredith M. Regan et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Journal of Clinical Oncology 27, no. 34 (December 2009) 5794-5799.; Culp, S. H., Tannir, N. M., Abel, E. J. et al.: Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer, 116: 3378, 2010; Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol. 2012;31:1305-1309.; Whitson JM, Reese AC, Meng MV. Factors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus. BJU Int. 2011;107:729-734.; Slaton JW, Derya Balbay M, Levy DA, et al. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Eur Urol. 1997;50:673-677; Naitoh J, Kaplan A, Dorey F, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol. 1999;162: 46-50.; Goetzl MA, Goluboff ET, Murphy AM, et al. A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survival. Urol Oncol. 2004;22:182-187.; Zisman A, Pantuck AJ, Chao DH, et al. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002;168: 962-967; Westesson, K. E., Klink, J. C., Rabets, J. C. et al.: Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy. Urology, 84: 1414, 2014; Qi Nienie,1 Pengjie Wu,2 Jinchao Chen, Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experienceWorld J Surg Oncol. 2017; 15: 4.; Abel EJ1, Spiess PE2, Margulis V Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 Mar 6. pii: S0022-5347(17)35378-8.; Janiszewska Anna Daria, Poletajew Sławomir ,Wasiutyński Aleksander Spontaneous regression of renal cell carcinomaContemp Oncol (Pozn). 2013; 17(2): 123–127; Shuch, B., Riggs, S. B., LaRochelle, J. C. et al.: Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int, 102: 692, 2008; Bigot, P., Fardoun, T., Bernhard, J. C. et al.: Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World Journal of Urology, 32: 109, 2014; Cost, N. G., Delacroix, S. E., Jr., Sleeper, J. P. et al.: The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. European Urology, 59: 912, 2011; Horn, T., Thalgott, M. K., Maurer, T. et al.: Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. Anticancer Res, 32:1729,2012; https://oncourology.abvpress.ru/oncur/article/view/710
-
3Academic Journal
Authors: A. V. Zyryanov, V. N. Oshchepkov, L. A. Burkhanova, А. В. Зырянов, В. Н. Ощепков, Л. А. Бурханова
Source: Cancer Urology; Том 13, № 2 (2017); 124-127 ; Онкоурология; Том 13, № 2 (2017); 124-127 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-2
Subject Terms: неоадъювантная таргетная терапия, palliative nephrectomy, sorafenib, neoadjuvant targeted therapy, паллиативная нефрэктомия, сорафениб
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/690/668; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].; Зырянов А.В., Федоров Н.М., Зотов П.Б., Ощепков В.Н. Анализ показателей заболеваемости и смертности от злокачественных новообразований населения Тюменской области. Академический журнал Западной Сибири 2016;12(3): 86–8. [Zyryanov A.V., Fedorov N.M., Zotov P.B., Oshchepkov V.N. Cancer incidence and mortality in the Tyumen Region. Akademicheskiy zhurnal Zapadnoy Sibiri = Academic Journal Siberia 2016;12(3):86–8. (In Russ.)].; Волкова М.И., Климов А.В., Черняев В.А. Паллиативная нефрэктомия: все ли больные нуждаются в операции? Злокачественные опухоли 2016;(4, спецвыпуск 1):115–8. [Volkova M.I., Klimov A.V., Chernyaev V.A. Palliative nephrectomy: do all patients require the surgery? Zlokachestvennye opukholi = Malignant Tumors 2016;(4, special edition 1):115–8. (In Russ.)].; Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099–109. DOI:10.1158/0008-5472.CAN-04-1443. PMID: 15466206.; Cowey C.L., Amin C., Pruthi R.S. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010;28(9):1502–7. DOI:10.1200/JCO.2009.24.7759. PMID: 20159822.; Fuhrman S.A., Lasky L.S., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655–63. PMID: 7180965.; https://oncourology.abvpress.ru/oncur/article/view/690
-
4Academic Journal
Source: Malignant tumours; № 4s1 (2016); 115-118 ; Злокачественные опухоли; № 4s1 (2016); 115-118 ; 2587-6813 ; 2224-5057
Subject Terms: таргетная терапия, паллиативная нефрэктомия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/299/269; NCCN Clinical Practice Guidelines in Oncology.2016. https://www.nccn.org/store/login/login.aspx? ReturnURL= https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf; Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–1659.; Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 2001;358(9286):966–970.; Flanigan R. C. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. / R. C. Flanigan, G. Mickisch, R. Sylvester et al. // J. Urol.– 2004.– Vol.171.– P. 1071–1076.; Beck J, Procopio G, Bajetta Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.// Ann Oncol. 2011 Aug;22(8):1812–23.; Hanna N, Sun M, Meyer CP et al. Survival Analyses of Metastatic Renal Cancer Patients Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study// J Clin Oncol. 2016 Sep 20;34(27):3267–75.; Heng M., W. Xie, M. M. Regan, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol, 27 (2009), pp. 5794–5799.; Bianchi M. J Urol 2012:187(4 Suppl): e724 (abs.1795); Hansen J. J Urol 2012:187(4 Suppl): e726(abs.1799); Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116(14):3378–3388.; D. Y. Heng, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794– 5799.; Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014 Oct;66(4):704–10.; Amin C, Wallen E, Pruthi RS, et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology. 2008;72(4):864–868.; Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181(2):518–523.; Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008;102(6):692–696.; Karakiewicz PI, Suardi N, Jeldres C, et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 2008;53(4):845–848.; Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28:1502–7.; Abel E., Culp S., Tannir N., Matin S., Tamboli P., Jonasch E., et al. (2011a) Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59: 10–15.; Escudier B., Bellmunt J., Negrie S. et al. Phase III trial of bevacizumab plus interferon alfa_2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival // J. Clin. Oncol.– 2010.– Vol.28.– P. 2144_2150.; Rini B., Halabi S., Rosenberg J. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal rell carcinoma: final results of CALGB90206 // J. Clin. Oncol.– 2010.– Vol.28.– P. 2137_2143.; Motzer R. J., Hutson T. E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal_cell carcinoma // N. Engl. J. Med.– 2007.– Vol.356.– P. 115_124.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal_Cell Carcinoma // N. Engl. J. Med.– 2007.– Vol.356.– P. 2271_2281.; Sternberg C., Davis I., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial // J. Clin. Oncol.– 2010.– Vol.28.– P. 1061.; Wood C., Margulis V. (2009) Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 115: 2355–2360.; Finelli A, Kaouk JH, Fergany AF, Abreu SC, Novick AC, Gill IS. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int. 2004;94(3):291–294.; Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology. 2006;68(3):528–532.; Eisenberg MS, Meng MV, Master VA, et al. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol. 2006;20(7):504–508.; Trinh QD, Sukumar S, Schmitges J, et al. Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. Ann Surg Oncol. 2013;20(6):2096–2102.; https://www.malignanttumors.org/jour/article/view/299; undefined
Availability: https://www.malignanttumors.org/jour/article/view/299
-
5Academic Journal
Subject Terms: рак почки, паллиативная нефрэктомия, таргетная терапия
File Description: text/html
-
6Academic Journal
Authors: A. V. Klimov, M. I. Volkova, V. I. Shirokograd, S. A. Kalinin, M. V. Peters, V. B. Matveev, А. В. Климов, М. И. Волкова, В. И. Широкорад, С. А. Калинин, М. В. Петерс, В. Б. Матвеев
Source: Cancer Urology; Том 11, № 3 (2015); 24-33 ; Онкоурология; Том 11, № 3 (2015); 24-33 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-3
Subject Terms: соматический статус, targeted therapy, palliative nephrectomy, prognostic factors, progression-free survival, overall survival, postoperative complications, adverse events, toxicity, somatic status, таргетная терапия, паллиативная нефрэктомия, факторы прогноза, беспрогрессивная выживаемость, общая выживаемость, послеоперационные осложнения, нежелательные явления, токсичность
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/484/450; Coppin C., Porzsolt F., Autenrieth M. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, p. CD001425.; Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa- 2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–9.; Mickisch G.H., Garin A., van Poppel H. et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group Radical nephrectomy plus nterferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–70.; Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.; Coppin C., Le L., Porzsolt F. et al. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008;(2):CD006017.; Conti S.L., Thomas I.C., Hagedorn J.C. et al.Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 2014;134:2245–52.; Escudier B., Bellmunt J., Negrie S. et al. Phase III trial of bevacizumab plus interferon alfa_2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol 2010;28:2144–50.; Rini B., Halabi S., Rosenberg J. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal rell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137–43.; Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal_cell carcinoma. N Engl J Med 2007;356:115–24.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal–cell carcinoma. N Engl J Med 2007;356:2271–81.; Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312–8.; Sternberg C., Davis I., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061.; Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomized, placebo_controlled phase III trial. Lancet 2008;372:449–56.; Abdollah F., Sun M., Thuret R. et al. Mortality and morbidity after cytoreductive ephrectomy for metastatic renal cell carcinoma: a populationbased study. Ann Surg Oncol 2011;18:2988–96.; Chapin B.F., Delacroix S.E., Culp S.H. et al. Post operative complications from cytoreductive nephrectomy after pre-surgical targeted therapy for metastatic renal cell carcinoma. AUA Annual Meeting, 2011.; Beck J., Procopio G., Bajetta E. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expandedaccess study: a large open-label study in diverse community settings. Ann Oncol 2011;22(8):1812–23.; Heng Daniel Y.C., Wells J. Connor, Rini Brian I. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66:704–10.; Choueiri T.K., Xie W., Kollmannsberger C. et al.The impact of cytoreductive ephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:60–6.; Warren M., Venner P.M., North S. et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2009;3(4):281–9.; Heng M., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794–9.; https://oncourology.abvpress.ru/oncur/article/view/484
-
7Academic Journal
Authors: М. И. Волкова, А. В. Климов
Source: Malignant tumours; Том 2, № 2 (2012); 57-59 ; Злокачественные опухоли; Том 2, № 2 (2012); 57-59 ; 2587-6813 ; 2224-5057
Subject Terms: таргетная терапия, паллиативная нефрэктомия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/115/120; Hudes G, Carducci M, Tomczak P, et al. Words of Wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.N Engl J Med. 2007;356(22):2271-2281.; Motzer RJ, Hutson TE, Tomczak P, et al. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.; Motzer RJ, Escudier B, Oudard S, et al. Effi cacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456.; Sternberg C, Szczylik E, Lee PV, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 27:15s, 2009 (suppl; abstr 5021^); Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655-1659.; Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 2001;358(9286):966-970.; Choueiri TK, Xie W, Kollmannsberger C, et al.The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60-66.; Barbastefano J, Garcia JA, Elson P, et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106(9):1266-1269.; Powles T, Blank C, Chowdhury S, et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol. 2011;60(3):448-454.; Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28(9):1502- 1507.; Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076-4081; Escudier B. Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol. 2011;22(5):995-996; https://www.malignanttumors.org/jour/article/view/115
-
8Academic Journal
Authors: КЛИМОВ А.В., ВОЛКОВА М.И., ШИРОКОРАД В.И., КАЛИНИН С.А., ПЕТЕРС М.В., МАТВЕЕВ В.Б., ОГОРОДНИКОВА Е.В.
File Description: text/html
-
9Academic Journal
Source: Злокачественные опухоли.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, рак почки, паллиативная нефрэктомия, таргетная терапия
File Description: text/html
-
10Academic Journal
Authors: ВОЛКОВА М.И., КЛИМОВ А.В.
File Description: text/html
-
11Academic Journal
Source: Онкоурология.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ДИССЕМИНИРОВАННЫЙ РАК ПОЧКИ,ТАРГЕТНАЯ ТЕРАПИЯ,ПАЛЛИАТИВНАЯ НЕФРЭКТОМИЯ,ФАКТОРЫ ПРОГНОЗА,БЕСПРОГРЕССИВНАЯ ВЫЖИВАЕМОСТЬ,ОБЩАЯ ВЫЖИВАЕМОСТЬ,ПОСЛЕОПЕРАЦИОННЫЕ ОСЛОЖНЕНИЯ,НЕЖЕЛАТЕЛЬНЫЕ ЯВЛЕНИЯ,ТОКСИЧНОСТЬ,СОМАТИЧЕСКИЙ СТАТУС, 3. Good health
File Description: text/html
-
12Academic Journal
Source: Злокачественные опухоли.
Subject Terms: 03 medical and health sciences, ДИССЕМИНИРОВАННЫЙ РАК ПОЧКИ,ПАЛЛИАТИВНАЯ НЕФРЭКТОМИЯ,ТАРГЕТНАЯ ТЕРАПИЯ, 0302 clinical medicine
File Description: text/html
